Opaleye Management Inc. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001595855
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 54 positions · Total reported value $757.89M · Top-10 concentration 65.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 50.0% · 13 new · 12 cut · 8 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +40.3% · vs SPY +25.5% · Prev Value $739.73M — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2025 13F filing, Opaleye Management Inc. disclosed 54 equity positions with a combined reported value of $757.89M. The filing implies a focused portfolio: its ten largest positions account for 65.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were HROW ($191.34M), LQDA ($84.98M), ETON ($48.36M). By sector, the heaviest allocations are Health Care 91.0%, Materials 1.8%. Versus the prior quarter, allocation shifted toward Other (+2.4pp), Materials (+1.7pp) and away from Health Care (-1.1pp), Industrials (-3.0pp).
Versus the prior quarter, Opaleye Management Inc. opened 13 new positions, trimmed 12 and fully exited 8, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 54% of names.
The largest new positions opened in Q4 2025 were CBIO ($13.97M), JBIO ($6.60M), URGN ($6.29M).
Of the 8 positions fully exited versus the prior quarter, the largest were IMNM ($37.30M), SRPT ($11.27M), LRMR ($10.56M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
- CBIO CRESCENT BIOPHARMA INC. · $13.97M
- JBIO JADE BIOSCIENCES INC · $6.60M
- URGN UROGEN PHARMA LTD · $6.29M
- CATX PERSPECTIVE THERAPEUTICS INC · $4.99M
- VYGR VOYAGER THERAPEUTICS INC · $4.70M
- RLMD RELMADA THERAPEUTICS INC · $4.52M
- TECX TECTONIC THERAPEUTIC INCORPORATED · $4.48M
- FBIO FORTRESS BIOTECH INC · $3.99M
Fully Exited (vs previous quarter)
- IMNM IMMUNOME INC · prev qtr: $37.30M
- SRPT SAREPTA THERAPEUTICS INC · prev qtr: $11.27M
- LRMR Larimar Therapeutics Inc · prev qtr: $10.56M
- ARVN ARVINAS INC · prev qtr: $8.42M
- TMCI TREACE MED CONCEPTS INC · prev qtr: $4.71M
- ADCT ADC THERAPEUTICS SA · prev qtr: $2.73M
- SYRE Spyre Therapeutics Inc · prev qtr: $1.09M
- PEPG PEPGEN INC · prev qtr: $346.50K
Insider Transactions (Form 4)
Latest Opaleye Management Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-05 | Buy | Grace Therapeutics, Inc. | 3,087 | $1.77 | SEC filing |
| 2026-11-04 | Buy | Grace Therapeutics, Inc. | 5,027 | $1.80 | SEC filing |
| 2026-11-03 | Buy | Grace Therapeutics, Inc. | 10,328 | $1.79 | SEC filing |
| 2026-10-26 | Buy | Grace Therapeutics, Inc. | 66,411 | $1.77 | SEC filing |
| 2026-10-23 | Buy | Alpha Cognition Inc. | 14,973 | $8.23 | SEC filing |
| 2026-10-22 | Buy | Alpha Cognition Inc. | 17,117 | $8.33 | SEC filing |
| 2026-10-22 | Buy | Grace Therapeutics, Inc. | 21,390 | $1.93 | SEC filing |
| 2026-10-19 | Buy | Grace Therapeutics, Inc. | 4,256 | $1.88 | SEC filing |
Fund Profile
Opaleye Management Inc. is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 58 US equity positions with a combined value of $1.10B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-78700 (status: Approved), registered 2013-10-29
- Regulatory AUM (Form ADV): $802.77M as of 2026-02-19
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
Portfolio Structure
- 58 positions · $1.10B reported value (Q2 2026)
- Top 10 holdings = 64.8% of reported value
- Largest position: LQDA (LIQUIDIA CORPORATION) at 17.7%
- Average position size: $19.04M
Sector Tilt
- Health Care 90.7%
- Materials 1.9%
- Industrials 1.4%
- (classified holdings cover 94% of value)
Quarterly Activity
- Q2 2026: 13 new, 14 added, 12 reduced, 8 exited
- 19 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
3.90M | $191.34M | 25.25% | Hold | |
| 2 |
|
2.44M | $84.98M | 11.21% | Reduce | |
| 3 |
|
2.86M | $48.36M | 6.38% | Hold | |
| 4 |
|
330.00K | $35.32M | 4.66% | Reduce | |
| 5 |
|
388.26K | $29.31M | 3.87% | Add | |
| 6 |
|
981.27K | $29.28M | 3.86% | Hold | |
| 7 |
|
695.00K | $22.06M | 2.91% | Add | |
| 8 |
|
1.59M | $19.36M | 2.56% | Hold | |
| 9 |
|
453.74K | $19.12M | 2.52% Form 4 · 5 → |
Add | |
| 10 |
|
410.00K | $17.02M | 2.25% | Hold | |
| 11 |
|
535.00K | $15.95M | 2.10% | Hold | |
| 12 |
|
200.00K | $15.88M | 2.10% | Add | |
| 13 |
|
6.29M | $14.84M | 1.96% | Add | |
| 14 |
|
1.18M | $13.97M | 1.84% | New | |
| 15 |
|
490.00K | $13.71M | 1.81% | Add | |
| 16 |
|
2.07M | $13.46M | 1.78% Form 4 · 11 → |
Add | |
| 17 |
|
2.60M | $13.05M | 1.72% | Hold | |
| 18 |
|
500.00K | $12.41M | 1.64% | Hold | |
| 19 |
|
6.79M | $11.07M | 1.46% | Reduce | |
| 20 |
|
105.00K | $9.17M | 1.21% | Hold | |
| 21 |
|
2.72M | $8.43M | 1.11% | Hold | |
| 22 |
|
260.00K | $8.20M | 1.08% | Add | |
| 23 |
|
100.00K | $7.96M | 1.05% | Hold | |
| 24 |
|
292.59K | $7.78M | 1.03% | Add | |
| 25 |
|
975.00K | $7.52M | 0.99% | Hold | |
| 26 |
|
930.00K | $6.84M | 0.90% | Reduce | |
| 27 |
|
427.61K | $6.60M | 0.87% | New | |
| 28 |
|
268.42K | $6.29M | 0.83% | New | |
| 29 |
|
535.00K | $5.22M | 0.69% | Reduce | |
| 30 |
|
1.18M | $4.99M | 0.66% | New | |
| 31 |
|
1.20M | $4.70M | 0.62% | New | |
| 32 |
|
935.00K | $4.52M | 0.60% | New | |
| 33 |
|
214.75K | $4.48M | 0.59% | New | |
| 34 |
|
2.48M | $4.46M | 0.59% | Reduce | |
| 35 |
|
345.10K | $4.32M | 0.57% | Reduce | |
| 36 |
|
1.09M | $3.99M | 0.53% | New | |
| 37 |
|
955.00K | $3.35M | 0.44% | New | |
| 38 |
|
390.84K | $3.11M | 0.41% | New | |
| 39 |
|
70.00K | $3.00M | 0.40% | Add | |
| 40 |
|
108.93K | $2.87M | 0.38% | Add | |
| 41 |
|
285.00K | $2.58M | 0.34% | New | |
| 42 |
|
251.93K | $2.27M | 0.30% | New | |
| 43 |
|
1.12M | $2.25M | 0.30% | Add | |
| 44 |
|
190.67K | $2.21M | 0.29% | New | |
| 45 |
|
900.00K | $1.97M | 0.26% | Add | |
| 46 |
|
1.40M | $1.89M | 0.25% | Add | |
| 47 |
|
310.00K | $1.76M | 0.23% | New | |
| 48 |
|
18.32K | $1.40M | 0.18% | New | |
| 49 |
|
75.00K | $1.18M | 0.16% | New | |
| 50 |
|
213.36K | $708.37K | 0.09% | New | |
FAQ
What did Opaleye Management Inc. buy in 2025-Q4?
In its 2025-Q4 13F filing, Opaleye Management Inc. reported 54 equity positions worth $757.89M in aggregate; its largest disclosed positions were HROW ($191.34M), LQDA ($84.98M), ETON ($48.36M).
How large is Opaleye Management Inc.'s portfolio?
Opaleye Management Inc. reported $757.89M of long equity holdings across 54 positions as of 2025-Q4. Top-10 holdings account for 65.5% of reported value.
What is Opaleye Management Inc.'s investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.